Skip to main content

Market Overview

Sanofi: Q4 Earnings Insights

Share:

 

Shares of Sanofi (NASDAQ:SNY) rose 2.7% in pre-market trading after the company reported Q4 results.

Quarterly Results

Earnings per share fell 3.33% over the past year to $1.45, which may not compare to the estimate of $0.69.

Revenue of $11,186,000,000 rose by 3.95% from the same period last year, which missed the estimate of $11,390,000,000.

Guidance

Sanofi hasn't issued any earnings guidance for the time being.

Sanofi hasn't issued any revenue guidance for the time being.

Details Of The Call

Date: Feb 05, 2021

Time: 07:30 AM

ET Webcast URL: https://sanofi.zoom.us/webinar/register/WN_wCfWJ37GRoKCqF1lYPCPhQ

Recent Stock Performance

Company's 52-week high was at $55.00

52-week low: $37.62

Price action over last quarter: Up 6.82%

Company Profile

Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Lantus, representing just under 10% of total sales. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.

 

Related Articles (SNY)

View Comments and Join the Discussion!

Posted-In: BZI-RecapsEarnings News

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com